Compare · CRMD vs NEXT
CRMD vs NEXT
Side-by-side comparison of CorMedix Inc. (CRMD) and NextDecade Corporation (NEXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while NEXT operates in Utilities - the two are in different parts of the market.
- NEXT is the larger of the two at $2.23B, about 14.4x CRMD ($155.0M).
- Over the past year, CRMD is down 38.7% and NEXT is down 1.9% - NEXT leads by 36.8 points.
- NEXT has been more active in the news (3 items in the past 4 weeks vs 2 for CRMD).
- NEXT has more recent analyst coverage (15 ratings vs 7 for CRMD).
- Company
- CorMedix Inc.
- NextDecade Corporation
- Price
- $8.95+2.17%
- $8.26-2.13%
- Market cap
- $155.0M
- $2.23B
- 1M return
- +19.17%
- -2.65%
- 1Y return
- -38.74%
- -1.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Oil & Gas Production
- Exchange
- AMEX
- NASDAQ
- IPO
- 2015
- News (4w)
- 2
- 3
- Recent ratings
- 7
- 15
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
NextDecade Corporation
NextDecade Corporation, a liquefied natural gas (LNG) development company, engages in the development activities related to the liquefaction and sale of LNG. It focusses on the development activities of Rio Grande LNG terminal facility located in the Port of Brownsville, southern Texas. The company is headquartered in Houston, Texas.
Latest CRMD
- CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
- Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
- SEC Form 10-Q filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
- SEC Form DEFA14A filed by CorMedix Inc.
- SEC Form DEF 14A filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest NEXT
- NextDecade Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- NextDecade Corporation Announces Appointment of John Zuklic as New Chief Financial Officer
- SEC Form DEFA14A filed by NextDecade Corporation
- Controller Boylston Luke covered exercise/tax liability with 1,312 shares, decreasing direct ownership by 0.59% to 219,509 units (SEC Form 4) (tax withholding)
- SEC Form S-3ASR filed by NextDecade Corporation
- Citigroup initiated coverage on NextDecade with a new price target
- NextDecade Provides First Quarter 2026 Business Update
- SEC Form DEF 14A filed by NextDecade Corporation
- SEC Form 8-K filed by NextDecade Corporation
- NextDecade Announces Timing of First Quarter 2026 Investor Call